A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab emtansine [Kadcyla]

Sponsor

Genentech, Inc.